DE602006015830D1 - Anti-il-23-antikörper - Google Patents
Anti-il-23-antikörperInfo
- Publication number
- DE602006015830D1 DE602006015830D1 DE602006015830T DE602006015830T DE602006015830D1 DE 602006015830 D1 DE602006015830 D1 DE 602006015830D1 DE 602006015830 T DE602006015830 T DE 602006015830T DE 602006015830 T DE602006015830 T DE 602006015830T DE 602006015830 D1 DE602006015830 D1 DE 602006015830D1
- Authority
- DE
- Germany
- Prior art keywords
- antibodies
- antigen
- binding portions
- subunit
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71133605P | 2005-08-25 | 2005-08-25 | |
US77235506P | 2006-02-10 | 2006-02-10 | |
PCT/US2006/032752 WO2007024846A2 (en) | 2005-08-25 | 2006-08-23 | Anit-il-23 antibiodies |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602006015830D1 true DE602006015830D1 (de) | 2010-09-09 |
Family
ID=37616511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602006015830T Active DE602006015830D1 (de) | 2005-08-25 | 2006-08-23 | Anti-il-23-antikörper |
Country Status (21)
Country | Link |
---|---|
US (1) | US7872102B2 (de) |
EP (1) | EP1937721B1 (de) |
JP (1) | JP5022367B2 (de) |
KR (1) | KR101028200B1 (de) |
AT (1) | ATE475672T1 (de) |
AU (1) | AU2006283194B9 (de) |
BR (1) | BRPI0615018A2 (de) |
CA (1) | CA2619052A1 (de) |
CY (1) | CY1110792T1 (de) |
DE (1) | DE602006015830D1 (de) |
DK (1) | DK1937721T3 (de) |
EA (1) | EA013506B1 (de) |
ES (1) | ES2347690T3 (de) |
HK (1) | HK1119712A1 (de) |
IL (1) | IL188312A0 (de) |
MX (1) | MX2008002179A (de) |
NO (1) | NO20081465L (de) |
PL (1) | PL1937721T3 (de) |
PT (1) | PT1937721E (de) |
SI (1) | SI1937721T1 (de) |
WO (1) | WO2007024846A2 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1896073T3 (pl) | 2005-06-30 | 2013-08-30 | Janssen Biotech Inc | Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania |
SG10201402712QA (en) | 2005-08-31 | 2014-08-28 | Merck Sharp & Dohme | Engineered anti-il-23 antibodies |
RS53685B1 (en) | 2005-12-29 | 2015-04-30 | Janssen Biotech Inc. | HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
TWI426918B (zh) * | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
JP2010518858A (ja) | 2007-02-23 | 2010-06-03 | シェーリング コーポレイション | 操作された抗−il−23p19抗体 |
EP2059534B1 (de) | 2007-02-23 | 2012-04-25 | Schering Corporation | Gentechnisch hergestellte anti-il-23p19-antikörper |
NZ579297A (en) | 2007-02-28 | 2012-03-30 | Schering Corp | Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders |
KR101709488B1 (ko) | 2007-08-10 | 2017-02-24 | 리제너론 파아마슈티컬스, 인크. | 인간 신경성장인자에 대한 고친화성 인간 항체 |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
AR068723A1 (es) * | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
AU2008328781A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
US8263748B2 (en) | 2008-08-27 | 2012-09-11 | Schering Corporation | Lyophilized formulations of engineered anti-IL-23p19 antibodies |
US8673630B2 (en) * | 2008-11-12 | 2014-03-18 | Merck, Sharp & Dohme Corp. | βGI-IgG intron for enhanced anti-IGF1R expression |
WO2010071800A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Feed supplement for mammalian cell culture and methods of use |
CA2757237A1 (en) | 2009-04-01 | 2010-10-14 | Jane Elizabeth Clarkson | Anti-il-23 immunoglobulins |
US20120264917A1 (en) * | 2009-05-27 | 2012-10-18 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
EP2456787A4 (de) * | 2009-07-24 | 2013-01-30 | Univ Leland Stanford Junior | Zytokinzusammensetzungen und verfahren zu ihrer verwendung |
WO2011017294A1 (en) | 2009-08-07 | 2011-02-10 | Schering Corporation | Human anti-rankl antibodies |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
WO2011079004A1 (en) | 2009-12-23 | 2011-06-30 | Schering Corporation | Cell line 3m |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
LT2635601T (lt) * | 2010-11-04 | 2016-10-10 | Boehringer Ingelheim International Gmbh | Antikūnai prieš il-23 |
EP2583979B1 (de) | 2011-10-19 | 2015-12-16 | Effimune | Verfahren zur Vorbereitung von menschlichem IL-23 gerichtete Antikörper, gegen die p19 |
JP6293120B2 (ja) * | 2012-05-03 | 2018-03-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗IL−23p19抗体 |
EP3456741B1 (de) | 2012-05-22 | 2020-12-16 | Bristol-Myers Squibb Company | Il-17a/f il-23 bispezifische antikörper und ihre verwendung |
US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
AR094877A1 (es) | 2013-03-08 | 2015-09-02 | Lilly Co Eli | Anticuerpos que se unen a il-23 |
AU2014228553B2 (en) | 2013-03-15 | 2019-01-24 | Amgen Inc. | Methods for treating Crohn's disease using an anti-IL23 antibody |
SG10201804954UA (en) | 2013-03-15 | 2018-07-30 | Amgen Inc | Methods for treating psoriasis using an anti-il-23 antibody |
JP2017524359A (ja) | 2014-07-24 | 2017-08-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−23a関連疾患の処置に有用なバイオマーカー |
MY192824A (en) | 2014-09-03 | 2022-09-12 | Boehringer Ingelheim Int | Compound targeting il-23a and tnf-alpha and uses thereof |
AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
US20160222102A1 (en) | 2015-02-04 | 2016-08-04 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
EA201792282A1 (ru) | 2015-04-14 | 2018-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способы лечения заболеваний |
CA2998349A1 (en) | 2015-09-17 | 2017-03-23 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
TWI733695B (zh) * | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
EP3393515A4 (de) | 2015-12-22 | 2019-08-14 | Amgen Inc. | Ccl20 als prädiktor der klinischen reaktion auf il23-antagonisten |
EP3974451A3 (de) | 2016-04-15 | 2022-07-06 | Boehringer Ingelheim International GmbH | Verfahren zur behandlung von entzündlichen erkrankungen |
US20180105588A1 (en) | 2016-10-14 | 2018-04-19 | Boehringer Ingelheim International Gmbh | Methods of treating diseases |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
MX2019013072A (es) | 2017-05-02 | 2019-12-16 | Merck Sharp & Dohme | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. |
AR112341A1 (es) | 2017-08-02 | 2019-10-16 | Lilly Co Eli | ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG |
CN112689643A (zh) | 2018-07-13 | 2021-04-20 | 阿斯特捷利康合作创业有限责任公司 | 用布雷库单抗治疗溃疡性结肠炎 |
US11548941B2 (en) | 2018-11-20 | 2023-01-10 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-IL-23 specific antibody |
US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
CN112807428A (zh) * | 2020-06-12 | 2021-05-18 | 江苏荃信生物医药有限公司 | 包含抗人白介素23单克隆抗体的药物组合物 |
CN112625129B (zh) * | 2020-11-26 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 一种抗人白介素23及包含其的试剂盒及其检测方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3045480B2 (ja) * | 1996-12-20 | 2000-05-29 | 大同メタル工業株式会社 | ボーリング盤 |
US6060284A (en) * | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
ATE474849T1 (de) * | 1998-04-14 | 2010-08-15 | Chugai Pharmaceutical Co Ltd | Neues cytokinartiges protein |
IL148300A0 (en) * | 1999-09-09 | 2002-09-12 | Schering Corp | Mammalian cytokines; related reagents and methods |
WO2004071517A2 (en) * | 2003-02-06 | 2004-08-26 | Schering Corporation | Uses of il-23 related reagents |
US7282204B2 (en) * | 2003-03-10 | 2007-10-16 | Schering Corporation | Uses of IL-23 agonists and antagonists; related reagents |
WO2005079837A1 (en) * | 2004-02-17 | 2005-09-01 | Schering Corporation | Methods of modulating il-23 activity; related reagents |
RS53685B1 (en) * | 2005-12-29 | 2015-04-30 | Janssen Biotech Inc. | HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS |
CN101662950A (zh) * | 2007-02-22 | 2010-03-03 | 希尔氏宠物营养品公司 | 用于促进骨发育的组合物和方法 |
-
2006
- 2006-08-23 PL PL06802075T patent/PL1937721T3/pl unknown
- 2006-08-23 AT AT06802075T patent/ATE475672T1/de active
- 2006-08-23 PT PT06802075T patent/PT1937721E/pt unknown
- 2006-08-23 JP JP2008528064A patent/JP5022367B2/ja not_active Expired - Fee Related
- 2006-08-23 MX MX2008002179A patent/MX2008002179A/es active IP Right Grant
- 2006-08-23 US US11/997,597 patent/US7872102B2/en not_active Expired - Fee Related
- 2006-08-23 KR KR1020087004323A patent/KR101028200B1/ko not_active IP Right Cessation
- 2006-08-23 BR BRPI0615018-7A patent/BRPI0615018A2/pt not_active IP Right Cessation
- 2006-08-23 CA CA002619052A patent/CA2619052A1/en not_active Abandoned
- 2006-08-23 EA EA200800417A patent/EA013506B1/ru not_active IP Right Cessation
- 2006-08-23 SI SI200630791T patent/SI1937721T1/sl unknown
- 2006-08-23 ES ES06802075T patent/ES2347690T3/es active Active
- 2006-08-23 DK DK06802075.9T patent/DK1937721T3/da active
- 2006-08-23 WO PCT/US2006/032752 patent/WO2007024846A2/en active Application Filing
- 2006-08-23 EP EP06802075A patent/EP1937721B1/de not_active Not-in-force
- 2006-08-23 DE DE602006015830T patent/DE602006015830D1/de active Active
- 2006-08-23 AU AU2006283194A patent/AU2006283194B9/en not_active Ceased
-
2007
- 2007-12-20 IL IL188312A patent/IL188312A0/en unknown
-
2008
- 2008-03-25 NO NO20081465A patent/NO20081465L/no not_active Application Discontinuation
- 2008-10-14 HK HK08111347.9A patent/HK1119712A1/xx not_active IP Right Cessation
-
2010
- 2010-09-23 CY CY20101100855T patent/CY1110792T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
MX2008002179A (es) | 2008-04-22 |
EA013506B1 (ru) | 2010-06-30 |
AU2006283194B9 (en) | 2011-02-03 |
BRPI0615018A2 (pt) | 2011-04-26 |
JP5022367B2 (ja) | 2012-09-12 |
US7872102B2 (en) | 2011-01-18 |
IL188312A0 (en) | 2008-04-13 |
EP1937721A2 (de) | 2008-07-02 |
KR101028200B1 (ko) | 2011-04-11 |
EA200800417A1 (ru) | 2008-06-30 |
CA2619052A1 (en) | 2007-03-01 |
AU2006283194B8 (en) | 2010-10-28 |
CY1110792T1 (el) | 2015-06-10 |
AU2006283194B2 (en) | 2010-10-21 |
EP1937721B1 (de) | 2010-07-28 |
NO20081465L (no) | 2008-05-15 |
JP2009506041A (ja) | 2009-02-12 |
HK1119712A1 (en) | 2009-03-13 |
SI1937721T1 (sl) | 2010-11-30 |
ATE475672T1 (de) | 2010-08-15 |
US20090240036A1 (en) | 2009-09-24 |
PL1937721T3 (pl) | 2010-12-31 |
KR20080031450A (ko) | 2008-04-08 |
AU2006283194A1 (en) | 2007-03-01 |
DK1937721T3 (da) | 2010-10-18 |
PT1937721E (pt) | 2010-09-17 |
WO2007024846A3 (en) | 2007-06-07 |
ES2347690T3 (es) | 2010-11-03 |
WO2007024846A2 (en) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE475672T1 (de) | Anti-il-23-antikörper | |
CY1121208T1 (el) | Σκευασματα αντισωματος ναταλιζουμαμπης | |
LTPA2017040I1 (lt) | Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui | |
TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
EA200870050A1 (ru) | Анти-il-17-антитела | |
MX2009001110A (es) | Anticuerpos monoclonales anti-il-6 y usos de los mismos. | |
MX2009006891A (es) | Anticuerpos cd44. | |
WO2014114651A9 (en) | Tnf-alpha antigen-binding proteins | |
NO20084878L (no) | Humanisert C-kit antistoff | |
EA200801362A1 (ru) | Пиримидинил бензотиофеновые соединения | |
UA92505C2 (ru) | Композиции на основе антитела против cd3 | |
EA200800953A1 (ru) | Человеческие моноклональные антитела к cd70 | |
ATE461220T1 (de) | Anti-egfr-antikörper | |
TW200740844A (en) | Novel MAdCAM antibodies | |
EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
TR201901841T4 (tr) | Her antikorlarının sabit dozlaması. | |
DE602006006200D1 (de) | Antikörper gegen 25-hydroxyvitamin d | |
EA200700225A1 (ru) | Аналоги тетрапептида | |
NZ592432A (en) | Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1) | |
EA200701452A1 (ru) | Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4) | |
EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
EA201390467A1 (ru) | Композиции антител и способы применения | |
EA200800601A1 (ru) | Связывающие fas антитела | |
EA201290977A1 (ru) | Гуманизированные антитела к il-25 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |